Skip to main content

bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.

Publication ,  Journal Article
Sinicrope, FA; Evans, DB; Leach, SD; Cleary, KR; Fenoglio, CJ; Lee, JJ; Abbruzzese, JL
Published in: Clin Cancer Res
December 1996

The bcl-2 proto-oncogene and the p53 tumor suppressor gene are important determinants of tumor cell susceptibility to apoptosis. bcl-2 and mutant p53 proteins inhibit apoptosis in vitro and can provide prognostic information in certain tumor types. We analyzed bcl-2 and p53 expression in archival pancreatic (n = 35) and ampullary (n = 6) adenocarcinomas, resected for cure, and their relationship to overall survival. Patients were treated with 5-fluorouracil and irradiation either pre- (n = 21) or postoperatively (n = 15); 5 patients received surgery alone. Using specific monoclonal antibodies, cytoplasmic bcl-2 and nuclear p53 proteins were detected in 22 of 40 (55%) and 20 of 37 (54%) tumors, respectively. No relationship was found between bcl-2 and p53 expression. Neither bcl-2 nor p53 correlated with histological response to preoperative chemoradiation. Lymph node involvement predicted poor overall survival (P = 0.02). A trend toward improved survival was seen in well-differentiated (P = 0.08) tumors and in those with increased bcl-2 expression (P = 0.06). p53 expression was not related to clinical outcome. In a multivariate analysis, nodal status was the single most important predictor of overall survival. Of note, the combined variable of bcl-2 expression and histological grade was a stronger prognostic variable than nodal status alone. Unlike nodal status, these features can potentially be evaluated in preoperative biopsy specimens.

Duke Scholars

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

December 1996

Volume

2

Issue

12

Start / End Page

2015 / 2022

Location

United States

Related Subject Headings

  • Tumor Suppressor Protein p53
  • Survival Analysis
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Mas
  • Prognosis
  • Pancreatic Neoplasms
  • Outcome Assessment, Health Care
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sinicrope, F. A., Evans, D. B., Leach, S. D., Cleary, K. R., Fenoglio, C. J., Lee, J. J., & Abbruzzese, J. L. (1996). bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res, 2(12), 2015–2022.
Sinicrope, F. A., D. B. Evans, S. D. Leach, K. R. Cleary, C. J. Fenoglio, J. J. Lee, and J. L. Abbruzzese. “bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.Clin Cancer Res 2, no. 12 (December 1996): 2015–22.
Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, et al. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996 Dec;2(12):2015–22.
Sinicrope, F. A., et al. “bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.Clin Cancer Res, vol. 2, no. 12, Dec. 1996, pp. 2015–22.
Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, Abbruzzese JL. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996 Dec;2(12):2015–2022.

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

December 1996

Volume

2

Issue

12

Start / End Page

2015 / 2022

Location

United States

Related Subject Headings

  • Tumor Suppressor Protein p53
  • Survival Analysis
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Mas
  • Prognosis
  • Pancreatic Neoplasms
  • Outcome Assessment, Health Care
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male